This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

ASCO 2017


This event has ended

At the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, Boehringer Ingelheim presented overall survival analysis of the LUME-Meso trial, results of the Phase III LUX-Head and Neck 2 trial and results of the first-in-man Phase I trial of the novel BET inhibitor, BI894999*.

For more details, please see below.

The full ASCO 2017 programme can be found here.


  • Saturday 3 June 2017

    Relevant oral presentation

    • Oral session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

      Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumors. (Abstract 2504)

      Aftimos et al.

  • Monday 5 June 2017

    Relevant oral presentations

    • Oral session: Head and Neck Cancer

      LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib** as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts). (Abstract 6001)

      Burtness et al.


    • Oral session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

      Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM) (Abstract 8506)

      Nowak et al.

How much do you know about Boehringer Ingelheim’s oncology pipeline and trials?

Take our quiz to find out

Didn’t make ASCO? find out more about upcoming oncology events.

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

**Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.

Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.